KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vir Biotechnology (VIR) Non-Current Deffered Revenue (2018 - 2025)

Vir Biotechnology's Non-Current Deffered Revenue history spans 8 years, with the latest figure at $9.4 million for Q3 2025.

  • For Q3 2025, Non-Current Deffered Revenue changed N/A year-over-year to $9.4 million; the TTM value through Sep 2025 reached $9.4 million, changed N/A, while the annual FY2023 figure was $1.5 million, 97.13% down from the prior year.
  • Non-Current Deffered Revenue for Q3 2025 was $9.4 million at Vir Biotechnology, up from $1.5 million in the prior quarter.
  • Across five years, Non-Current Deffered Revenue topped out at $55.5 million in Q2 2021 and bottomed at $1.5 million in Q4 2023.
  • The 5-year median for Non-Current Deffered Revenue is $7.6 million (2022), against an average of $25.5 million.
  • The largest annual shift saw Non-Current Deffered Revenue soared 1354.68% in 2021 before it plummeted 97.13% in 2023.
  • A 5-year view of Non-Current Deffered Revenue shows it stood at $3.8 million in 2021, then surged by 1294.68% to $53.2 million in 2022, then tumbled by 97.13% to $1.5 million in 2023, then changed by 0.0% to $1.5 million in 2024, then surged by 518.15% to $9.4 million in 2025.
  • Per Business Quant, the three most recent readings for VIR's Non-Current Deffered Revenue are $9.4 million (Q3 2025), $1.5 million (Q1 2024), and $1.5 million (Q4 2023).